171 related articles for article (PubMed ID: 18468446)
1. Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.
Colotta V; Catarzi D; Varano F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Traini C; Pugliese AM; Pedata F; Morizzo E; Moro S
Bioorg Med Chem; 2008 Jun; 16(11):6086-102. PubMed ID: 18468446
[TBL] [Abstract][Full Text] [Related]
2. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
[TBL] [Abstract][Full Text] [Related]
3. 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Calabri FR; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Deflorian F; Moro S
J Med Chem; 2004 Jul; 47(14):3580-90. PubMed ID: 15214785
[TBL] [Abstract][Full Text] [Related]
4. 4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Lenzi O; Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Varani K; Marighetti F; Morizzo E; Moro S
J Med Chem; 2006 Jun; 49(13):3916-25. PubMed ID: 16789747
[TBL] [Abstract][Full Text] [Related]
5. 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
Catarzi D; Colotta V; Varano F; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Montopoli C; Moro S
J Med Chem; 2005 Dec; 48(25):7932-45. PubMed ID: 16335918
[TBL] [Abstract][Full Text] [Related]
6. 1,2,4-Triazolo[1,5-a]quinoxaline derivatives: synthesis and biological evaluation as adenosine receptor antagonists.
Catarzi D; Colotta V; Varano F; Filacchioni G; Martini C; Trincavelli L; Lucacchini A
Farmaco; 2004 Feb; 59(2):71-81. PubMed ID: 14871498
[TBL] [Abstract][Full Text] [Related]
7. 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
Sarges R; Howard HR; Browne RG; Lebel LA; Seymour PA; Koe BK
J Med Chem; 1990 Aug; 33(8):2240-54. PubMed ID: 2374150
[TBL] [Abstract][Full Text] [Related]
8. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
[TBL] [Abstract][Full Text] [Related]
9. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
10. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
[TBL] [Abstract][Full Text] [Related]
11. 2-aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists.
Catarzi D; Colotta V; Varano F; Calabri FR; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Tralli A; Montopoli C; Moro S
Bioorg Med Chem; 2005 Feb; 13(3):705-15. PubMed ID: 15653338
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of 4-cycloalkylamino-1, 2, 4-triazolo[4, 3-a]quinoxalin-1- one derivatives as A1 and A3 adenosine receptor antagonists.
Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Lucacchini A; Colotta V
Arch Pharm (Weinheim); 2004 Jan; 337(1):35-41. PubMed ID: 14760626
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
[TBL] [Abstract][Full Text] [Related]
14. Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.
Morizzo E; Capelli F; Lenzi O; Catarzi D; Varano F; Filacchioni G; Vincenzi F; Varani K; Borea PA; Colotta V; Moro S
J Med Chem; 2007 Dec; 50(26):6596-606. PubMed ID: 18047262
[TBL] [Abstract][Full Text] [Related]
15. New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Preti D; Zaid AN; Saponaro G; Tabrizi MA; Baraldi S; Romagnoli R; Moorman AR; Varani K; Cosconati S; Di Maro S; Marinelli L; Novellino E; Borea PA
J Med Chem; 2011 Jul; 54(14):5205-20. PubMed ID: 21675777
[TBL] [Abstract][Full Text] [Related]
16. 1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists.
Colotta V; Catarzi D; Varano F; Cecchi L; Filacchioni G; Martini C; Trincavelli L; Lucacchini A
J Med Chem; 2000 Mar; 43(6):1158-64. PubMed ID: 10737748
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of 4-amino-6-(hetero)arylalkylamino-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent A(2A) adenosine receptor antagonists.
Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Lucacchini A
Bioorg Med Chem; 2003 Dec; 11(24):5509-18. PubMed ID: 14642595
[TBL] [Abstract][Full Text] [Related]
18. 1,2,4-triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A₃ receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies.
Catarzi D; Varano F; Poli D; Squarcialupi L; Betti M; Trincavelli L; Martini C; Dal Ben D; Thomas A; Volpini R; Colotta V
Bioorg Med Chem; 2015 Jan; 23(1):9-21. PubMed ID: 25497490
[TBL] [Abstract][Full Text] [Related]
19. Highly potent and selective fluorescent antagonists of the human adenosine A₃ receptor based on the 1,2,4-triazolo[4,3-a]quinoxalin-1-one scaffold.
Vernall AJ; Stoddart LA; Briddon SJ; Hill SJ; Kellam B
J Med Chem; 2012 Feb; 55(4):1771-82. PubMed ID: 22277057
[TBL] [Abstract][Full Text] [Related]
20. 1,3-dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships.
Fernández F; Caamaño O; Isabel Nieto M; López C; García-Mera X; Stefanachi A; Nicolotti O; Isabel Loza M; Brea J; Esteve C; Segarra V; Vidal B; Carotti A
Bioorg Med Chem; 2009 May; 17(10):3618-29. PubMed ID: 19398343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
